Latest Breaking News On - Williamh collier - Page 3 : comparemela.com

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 21, 2022 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target. | April 21, 2022

Lisam caperelliWilliamh collierInternational dialArbutus biopharma corporation nasdaqArbutus biopharma corporationGlobenewswire incBiopharma corporationDial in numberArbutus biopharma corporation stock exchangePress releaseHat abus ca03879j1003

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesLisam caperelliWilliam collierWilliamh collierGenevant sciencesUnited states courtArbutus biopharma corporation nasdaqModerna incSecurities exchangeUs district courtBiopharma corporationFederal circuitAppeal boardLooking statementsSecurities actSecurities exchange act

Arbutus Biopharma : Preliminary Data Shows that Arbutus Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity - Form 8-K

Preliminary Data Shows that Arbutus Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity WARMINSTER, Pa., Dec. 01, 2021 . | December 1, 2021

United statesGaston picchioLisam caperelliWilliamh collierArbutus biopharma corporation nasdaqWorld health organizationSecurities exchangePreliminary data showsArbutu capsid inhibitorGenerally safeProvides robust antiviralBiopharma corporationChief development officerLooking statementsSecurities actSecurities exchange act

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused…

Lisam caperelliWilliamh collierArbutus biopharma corporation nasdaqPostmedia network incSecurities exchangeArbutus announces late breaker abstract acceptedLiver meetingArbutus biopharma corporationAmerican associationLiver diseasesDigital experiencePresentation detailsLate breaking abstractSession scheduleBiopharma corporationSecurities act

Arbutus Appoints Lisa M Caperelli as Vice President, Investor Relations

Arbutus Appoints Lisa M Caperelli as Vice President, Investor Relations
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesLisam caperelliDavid hastingsLisa caperelliWilliamh collierArbutus biopharma corporationNational investors relations instituteDelaware valley universityAdvaxis incMarinus pharmaceuticalsWindtree therapeutics incArbutus biopharma corporation nasdaqBusiness administrationVice presidentInvestor relationsArbutu chief financial